Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7936 to 7950 of 8905 results

  1. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  2. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  3. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Withdrawn guidance

  4. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  5. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  6. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Withdrawn guidance

  7. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Withdrawn guidance

  8. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  9. Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)

    This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].

    Withdrawn guidance

  10. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  11. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  12. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Withdrawn guidance

  13. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Withdrawn guidance

  14. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA175)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  15. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Withdrawn guidance